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Glial cells are functionally impaired in
juvenile neuronal ceroid lipofuscinosis
and detrimental to neurons
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Payam Rezaie3, Giovanna Lalli4, Simon Pope5, Simon J. Heales5, Hannah M. Mitchison5, Brenda P. Williams1†
and Jonathan D. Cooper1,6*†
Abstract
The neuronal ceroid lipofuscinoses (NCLs or Batten disease) are a group of inherited, fatal neurodegenerative disorders of
childhood. In these disorders, glial (microglial and astrocyte) activation typically occurs early in disease progression and
predicts where neuron loss subsequently occurs. We have found that in the most common juvenile form of NCL (CLN3
disease or JNCL) this glial response is less pronounced in both mouse models and human autopsy material, with
the morphological transformation of both astrocytes and microglia severely attenuated or delayed. To investigate
their properties, we isolated glia and neurons from Cln3-deficient mice and studied their basic biology in culture.
Upon stimulation, both Cln3-deficient astrocytes and microglia also showed an attenuated ability to transform
morphologically, and an altered protein secretion profile. These defects were more pronounced in astrocytes,
including the reduced secretion of a range of neuroprotective factors, mitogens, chemokines and cytokines, in
addition to impaired calcium signalling and glutamate clearance. Cln3-deficient neurons also displayed an abnormal
organization of their neurites. Most importantly, using a co-culture system, Cln3-deficient astrocytes and microglia had a
negative impact on the survival and morphology of both Cln3-deficient and wildtype neurons, but these effects were
largely reversed by growing mutant neurons with healthy glia. These data provide evidence that CLN3 disease astrocytes
are functionally compromised. Together with microglia, they may play an active role in neuron loss in this disorder and
can be considered as potential targets for therapeutic interventions.
Keywords: Juvenile batten disease, CLN3 disease, Neuronal ceroid lipofuscinosis, Neuron-glial interactions, Astrocyte and
microglial dysfunction
Introduction
The neuronal ceroid lipofuscinoses (NCLs) or Batten
disease are a group of fatal lysosomal storage disorders,
and are collectively the most common cause of childhood
dementia [91]. Each form of NCL is caused by mutations
in a different gene, which determines the age of disease
onset, symptoms and rate of disease progression, but all
are fatal after a period of prolonged disability [79, 96].
Very little is known about how mutations in these genes
lead to devastating effects upon the brain, but these
diseases share common pathological features, including
accumulation of autofluorescent storage material within
the lysosome and profound neuronal loss [2, 25, 63].
Clues to understanding NCL pathogenesis have come
from studying mouse models [13, 23, 24, 82]. Although
neuron loss is widespread at the end stages of disease, there
is remarkable selectivity in its earlier stages with these
effects being most prominent within the thalamocortical
system and the cerebellum, as reviewed in [24, 25, 63].
However, no direct relationship has been found between
this pattern of neuron loss and storage material accumula-
tion [24, 25, 63]. Instead, localized glial activation
* Correspondence: jonathan.cooper@labiomed.org
†Equal contributors
1Department of Basic and Clinical Neuroscience, King’s College London,
Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical
Neuroscience Institute, 5 Cutcombe Road, London SE5 9RX, UK
6Department of Pediatrics, Harbor-UCLA Medical Center, Los Angeles
Biomedical Research Institute and David Geffen School of Medicine UCLA,
1124 West Carson Street, Hanley Hardison Building, Torrance, CA 90502, USA
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Parviainen et al. Acta Neuropathologica Communications  (2017) 5:74 
DOI 10.1186/s40478-017-0476-y
consistently occurs early in NCL disease progression,
and its distribution accurately predicts where neuron
loss subsequently occurs, as reviewed in [25, 63]. There is
also evidence from human autopsy material that neuron
loss is greatest where astrocytosis and microglial activa-
tion is most pronounced [2, 37, 90].
In the most common juvenile form of NCL (JNCL or
CLN3 disease) the activation of both astrocytes and
microglia appears to be attenuated compared to other
earlier onset forms of NCL [68, 69, 90]. We have ex-
plored this issue in more detail in this study, as such
observations raise the possibility that normal glial func-
tion may be compromised by CLN3 deficiency. Since
both astrocytes [66, 85] and microglia [5] are crucial
for proper neuron function and survival, as well as
playing a pivotal role in the pathogenesis of CNS dis-
eases, any deficits in the biology of these cells could
significantly impact upon neuronal health. Indeed, re-
cent evidence suggests that this could be the case in
CLN3 disease, with a potential influence of both micro-
glia and astrocytes [16, 99]. There is also evidence in
CNS disease and injury that astrocytes may be primed
by microglia to directly harm neurons [49], raising the
possibility that glia may actively contribute to the patho-
genesis of a range of disorders. Furthermore, astrocyte
dysfunction is suggested to trigger neurodegeneration spe-
cifically in lysosomal storage disorders, for example in
multiple sulfatase deficiency [28], and in Niemann-Pick
disease type C [21].
In this study, we have explored the role of glia in
CLN3 disease using primary cultures of microglia,
astrocytes and neurons derived from Cln3-deficient
mice. Grown in isolation, both types of glia responded
atypically to stimulation and displayed altered protein
secretion profiles. These differences were more pro-
found in astrocytes, which displayed a disrupted actin
and intermediate filament cytoskeleton and an im-
paired ability to propagate a calcium signal and clear
glutamate, suggesting that neuron-glial communication
may be impaired in the JNCL brain. Cortical neurons
from these mice displayed altered neurite branching, sug-
gesting neurons are also compromised by Cln3 deficiency.
In a mixed glial-neuron co-culture system, we found that
Cln3-deficient glial cells had a significant negative impact
upon the survival and morphology of both Cln3-deficient
and wild type neurons, but that the defects found in mutant
neurons could be markedly improved by the presence of
healthy astrocytes and microglia.
These findings provide further new information on
how both glia and neurons are compromised in this dis-
order and the negative role that glial cells appear to play
in the pathogenesis of CLN3 disease, and also highlight
astrocytes and microglia as novel potential targets for
future therapeutic approaches.
Materials and methods
Animals
Homozygous Cln3Δex1–6 mice (Cln3−/−) were used as a
model of CLN3 disease [56] and cells isolated from early
postnatal mice for tissue culture, as described below,
and were also assessed histologically. For histological
comparisons of the level of glial activation, homozygous
Tpp-1-deficient mice (Tpp-1−/−) were used as a model of
CLN2 disease (Late Infantile NCL) [84]. Wild type (WT)
mice on the same strain (C57BL/6 J) background were
used as controls. All animal housekeeping and proce-
dures were carried out according to the UK Scientific
Procedures (Animals) Act (1986). Cln3−/− mice were an-
alyzed histologically at 6.5 months (early symptomatic),
12 months (disease mid stage), and 22 months of age
(severely affected), and Tpp-1−/− mice histologically at
4 months of age (severely affected).
Human tissues
Human specimens were obtained from the Human Brain
and Spinal Fluid Resource Centre, Los Angeles and the
MRC London Neurodegenerative Diseases Brain Bank,
Institute of Psychiatry, King’s College London following
routine autopsies of NCL patients with informed written
consent from their families. At autopsy, tissues were
fixed immediately by immersion in 4% neutral buffered
formaldehyde and subsequently processed and embed-
ded in paraffin wax. These cases included NCL patients
with CLN2 (n = 2; 6 years old Female, 26 years Male),
CLN3 (n = 2; 20 years old Male, 24 years old Female),
neurologically normal controls (n = 2 ages 25 years
Male, 26 years Female). Study protocols for the use of
human material were approved by the Ethical Research
Committees of the Institute of Psychiatry (approval
numbers 223/00, 181/02).
Histological analysis
To investigate glial activation in the mouse brain, frozen
sections from Cln3−/−, Tpp-1−/− and WT mice were
prepared as previously described [8, 40, 68, 69]. To in-
vestigate glial activation in the human NCL brain,
paraffin-embedded tissue blocks were prepared from
the primary visual cortical region of human CLN2 and
CLN3 autopsy tissue (n = 2 for each type of NCL), and
cut into 8 μm sections, as previously described [18, 90].
Both mouse and human sections containing the primary
visual cortex were immunostained with antibodies to glial
fibrillary acidic protein (GFAP, 1:1000 for mouse tissue,
1:5000 for human tissue, rabbit polyclonal, Dako) to iden-
tify activated astrocytes and Cluster of Differentiation 68
(CD68, 1:150, Rat monoclonal, Serotec) to identify activated
microglia [54, 59, 71]. Immunostaining was detected using
VECTASTAIN Elite ABC Reagent (Vector Laboratories)
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and DAB substrate (Sigma) and human sections counter-
stained with hematoxylin [18, 90].
Tissue culture
Glial cultures
Mixed glial cells were isolated from post-natal day 1–4
(P1-P4) Cln3−/− or WT mouse cerebral cortices, as previ-
ously described [52, 97]. Once these cultures reached con-
fluence they were composed of a base layer of non-dividing
astrocytes and an upper layer of dividing microglia and a
few oligodendrocytes. Microglial cultures were isolated
from these P2-P4 mixed glial cultures by shaking at
180 rpm for 10-12 h at 37°C in a humidified incubator 5%
CO2 [97]. Cells were harvested, re-suspended in RPMI
1640 (Gibco, Invitrogen) supplemented with penicillin/
streptomycin (100 U/mL, 100 mg/mL, Sigma, UK), 5% FBS
(Gibco, Invitrogen) and 2 mM L-Glutamine (Sigma), plus
macrophage colony-stimulating factor (M-CSF, 10 ng/ml)
and granulocyte macrophage colony-stimulating factor
(GM-CSF, 10 ng/ml) (both R&D Systems, Minneapolis,
MN) to promote proliferation [35, 87], then plated at a con-
centration of 1–2 × 105 cells per flask on poly-D-lysine
(PDL, 25μg/ml, Sigma) coated T25 (Corning, Costar) flasks.
To generate astrocyte cultures (from P1-P2 mice), micro-
glia were removed, as described above, and these confluent
astrocyte monolayers were treated with Ara-C (Arabinofur-
anosyl Cytidine, 2 × 10−5 mol/l) for 7 days to abolish any
remaining dividing cells. As such, at the start of all experi-
ments described, these glial cells had been cultured for ap-
proximately 21 days (astrocytes) or 12–14 days (microglia).
All cultures used in these studies exhibited a purity of >98%
(astrocytes) or >99% (microglia) at one week after plating,
as determined by immunofluorescence staining, but their
composition may subsequently vary over time under some
culture conditions.
Neuronal cultures
Cells were isolated from P0 WT or Cln3−/− mouse cerebral
cortices as described previously [10, 11] and plated on PDL
coated (50 μg/ml), 13 mm glass coverslips (VWR) in 24
well plates (Corning, Costar) at a concentration of 2.5–
3 × 105 cells per coverslip.
Neuron-glia co-cultures
Co-cultures were generated by plating 50,000 mixed WT
or Cln3−/− glial cells from 3 to 4 week old cultures
directly on top of 7 day old neuronal cultures.
Pharmacological activation of glial cells
Microglial cells were activated by exposure to lipopoly-
saccharide (LPS, 1 μg/ml LPS, Sigma), while astrocytes
were activated by exposure to LPS plus interferon-gamma
(IFN-γ, 100 U/ml, Thermo Scientific) [12, 14]. The ability
of mutant and WT glia to respond similarly to LPS and
IFN-γ was assessed by studying the nuclear translocation
of the downstream phosphorylated proteins, NF-κβ sub-
unit P65 (P-P65) [22] or STAT1 (P-STAT1) [39] respect-
ively, using phospho-specific primary antibodies (P-P65,
1:100; P-STAT1, 1:50, both from Cell Signaling).
Immunofluorescence staining
Cultures were immunostained using standard protocols
(see [9]). Where appropriate, nuclei were counterstained
with DAPI (4′-6-Diamidino-2-phenylindole, 0.5-1 μg/ml,
Sigma) and coverslips mounted using either Fluoromount
G or Prolong gold (Southern Biotech). The composition of
all cultures was assessed using cell-type specific markers.
GFAP (rabbit polyclonal, 1:500, Dako) or glutamate synthe-
tase (rabbit polyclonal, 1:500, Abcam) was used to identify
astrocytes, O4 (monoclonal antibody, 1:100, Covance) to
identify oligodendrocytes, CD68 (Rat monoclonal, 1:500,
Serotec) to identify microglia and MAP2 (monoclonal anti-
body, 1:1000, Abcam) and/or NeuN (monoclonal antibody,
1:100, Chemicon) to identify neurons. For cytoskeletal ana-
lysis, phalloidin was used to visualize F-actin filaments and
α- and β- tubulin antibodies to visualize microtubular
organization (monoclonal and polyclonal antibodies re-
spectively, both from Sigma and used at 1:1000). All
secondary antibodies were obtained from Invitrogen,
and used at a dilution of 1:1000 (Alexa 488, 546, 633
and biotinylated antibodies) or 1:5000 (Alexa 790, 680).
Immunofluorescently stained cells were visualized using
a Zeiss AxioImager Z1 fluorescence microscope (Carl
Zeiss, Ltd) with a monochrome AxioCamMR3 camera
using AxioVision 4.8. Imaging software (Carl Zeiss,
Welwyn Garden City).
Cell death assays
The overall cytotoxicity in co-cultures was evaluated by
measuring lactate dehydrogenase (LDH) release using a
Cytotox 96 assay kit (Promega) according to manufac-
turer’s instructions. Total LDH content (100% LDH) was
determined by lysing cultures in 0.1% Triton X-100 for
30 min, and LDH release from cells was expressed as a
percentage of total LDH (%LDH) in each sample. To
reveal the identity of the cells undergoing cell death, a
live/dead fixable cellular marker conjugated to a red
fluorochrome (Invitrogen) was used, according to the
manufacturer’s instructions, in association with relevant
cell-type specific markers.
Assessment of morphological changes following activation
Astrocyte cultures were immunostained with GFAP and
images of 10 random fields of cells, whose processes
were not overlapping, were taken and cell soma size
measured using ImageJ (National Institutes of Health,
Bethesda, MD). The average cell soma size of Cln3−/−
astrocytes was normalized to the corresponding values
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from WT astrocytes. To assess the morphological re-
sponse of microglia to activation, cells were classified
into 3 subcategories [98]: type 1 cells – microglia with
extended processes (non-activated); type 2 cells – micro-
glia with retracted processes (partly activated); type 3
cells– rounded cells with a small soma (fully activated),
and the percentage of each morphological type present
(determined from counting 10 random fields per cul-
ture) was calculated for each culture condition.
Protein secretion analysis
The quantitative analysis of the levels of proteins
secreted by Cln3−/− and WT glial cells grown under
basal conditions and at various time points (between 6 h
and 96 h) after activation with LPS/IFNγ was carried out
by Myriad RBM (Austin, TX, USA, RodentMAP version
2.0 cytokine analysis). Simultaneous analysis of 59 differ-
ent proteins was carried out on three different biological
samples for each treatment per genotype using an auto-
mated quantification system. The values obtained were
normalized to the relative number of cells in the culture
from which the medium was collected, as determined by
counting DAPI stained nuclei.
Glutathione measurements
The intracellular levels of reduced (GSH) and oxidized
(GSSG) glutathione was determined in WT and Cln3
−/−astrocytes. Samples for these measurements were gen-
erated from stimulated (for 24 or 48 h) and non-
stimulated cultures by trypsinization and resuspension of
cells in 300μl of isolation medium (320 mM sucrose,
10 mM Tris, 1 mM EDTA, pH 7.4), and the sample split
into two for testing. One half was used to quantify GSH
levels by separating this antioxidant from other compo-
nents within the sample using reverse-phase high per-
formance liquid chromatography (HPLC) followed by
detection using an electrochemical method [33]. The GSH
levels obtained were normalized to the total amount of
protein, as determined using a Lowry protein assay
(Thermo Scientific). The other half of the sample was used
to determine the presence of GSSG. This was carried out
by treating samples with glutathione reductase (GR) in the
presence of reduced nicotinamide adenosine dinucleotide
phosphatase (NADPH) to convert GSSG to GSH [86], and
the level determined by HPLC as before. This gives a
measure of the total glutathione within the cell. The dif-
ference between total glutathione concentration and
GSH concentration was then used to calculate the con-
centration of GSSG. Finally, glutathione levels in the
culture medium were measured using the GSH-Glo
glutathione assay kit (Promega), according to manufac-
turer’s instructions. In some experiments, the effect of
actin depolymerisation on glutathione secretion was
assessed by treating WT astrocytes with Cytochalasin D
(1 μM), an inhibitor of actin polymerization.
Intracellular calcium measurements
Fluctuations in the levels of intracellular Ca2+ ([Ca2+]i) were
examined to determine the ability of WTand Cln3−/− astro-
cytes to generate calcium waves when exposed to ATP
(100 μM) as described previously [60]. To measure intracel-
lular Ca2+ levels, cells were loaded with 5 μM of Fura-2-
acetoxymethyl ester (Fura-2 AM, Invitrogen), which is a
membrane permeable derivative of the ratiometric calcium
indicator Fura-2, for 30 min at room temperature and ex-
cess reagent removed by washing. Fluorescence measure-
ments were carried out at room temperature using an
epifluorescence inverted microscope equipped with a 20X
fluorite objective over a 30–45 min period. [Ca2+]i was
monitored in single cells, with the excitation light provided
by a Xenon arc lamp, using a monochromator (Cairn
Research) to excite fluorescence sequentially at 340,
380 nm (all at 10 nm bandwidth). Using a long pass filter
from 510 nm, the emitted fluorescence light was reflected
and then transferred to a frame transfer cooled CCD cam-
era (Hamamatsu Orca ER).
Glutamate uptake assay
The glutamate clearance capacity of WT and Cln3−/− as-
trocytes was determined using a Glutamate Assay kit
(Abcam), according to manufacturer’s instructions. Values
were normalized to the amount of total protein in each
sample, determined using a BCA protein assay kit
(Thermo Scientific).
Cell mobility assay
The ability of Cln3−/− astrocytes to migrate was assessed
by performing a scratch wound assay. A scratch was
made in confluent astrocyte cultures grown on Essen
Image Lock 24-well plates using an Essen Wound-
maker, generating an 800–900 μm wide cell-free region.
Cultures were then placed in the IncuCyte live cell im-
aging system (Essen) and the wound width measured
every hour for 24 h [62]. The rate of migration was ob-
tained by measuring the width of the existing wound
over time.
Neurite complexity measurements
Neurite complexity was analyzed in P0 cortical neuron
cultures from WT and Cln3−/− mice after 7 DIV using
ImageJ software to analyze immunofluorescence images
of MAP2-positive cortical neurons, measuring 40 cells
per genotype per experiment. The number of primary,
secondary, and tertiary neurites present on each neuron
was counted, the area of its cell soma measured, to-
gether and the total length of all primary neurites and
the length of the longest primary neurite (assumed to
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represent the axon). Similar measurements of neurite
complexity and soma size were also obtained from neu-
rons co-cultured with glial cells.
Statistics
All quantitative data was collected using Microsoft Excel
spreadsheets, and analyzed using Graphpad PRISM.
Where appropriate the data were normalized to values
from untreated WT cultures. Most frequently, to allow
comparisons of groups, one-way ANOVA with Bonferroni
correction was used to test for statistical significance.
However, when two groups were compared with each
other a Student’s T-test was used. In general, three tech-
nical replicates were used, and independent experiments
were repeated at least three times (unless otherwise
stated). Data was presented as mean ± SEM and changes
were considered significant with a p-value of ≤0.05. P-
values ≤0.05 marked with *, P-values ≤0.01 marked with
**, P-value ≤0.001 marked with ***.
Results
Attenuated glial response in human CLN3 disease
In moderately affected Cln3−/− mice the reactive re-
sponse of glia, judged by hallmark morphological
changes, appears attenuated compared to earlier onset
forms of NCL [68, 69]. To investigate this possibility fur-
ther we extended our analysis to more aged and severely
affected Cln3−/− mice, and also investigated the extent of
glial activation in the same cortical region in hu-
man CLN3 disease autopsy tissue.
We compared the extent of gliosis in the primary
visual cortex (V1) of Cln3−/− mice, (from 6.5–21 months
of age) with that of wildtype controls and Tpp-1−/− mice
(at 4 months of age, representing disease end stage), a
model for CLN2 disease [84], an earlier onset and more
rapidly progressing type of NCL [4]. In V1 of these
severely affected Tpp-1−/− mice, the morphological fea-
tures characteristic of reactive astrocytosis were evident
within these astrocytes, with intense GFAP immunoreac-
tivity, thickened processes and pronounced hypertrophy
(Fig. 1a). This astrocytosis in Tpp-1−/− mice displayed
laminar specificity, being most pronounced in laminae II
and III, V and VI.
In comparison, in V1 of Cln3−/− mice, GFAP immuno-
reactivity revealed a markedly different extent of astrocy-
tosis, with substantial differences in astrocyte morphology.
Apart from a small population of darkly immunostained
astrocytes present in the most ventral portion of lamina
VI, the majority of astrocytes in V1 of presymptomatic
6.5 month old Cln3−/− mice displayed a protoplasmic
morphology with numerous thin processes, compared to
the characteristic appearance of fully activated astrocytes
in Tpp-1−/− mice (Fig. 1a). Initially largely confined to
laminae I and IV, these protoplasmic astrocytes became
Fig. 1 Attenuated glial responses in Cln3−/− mouse tissue and in human
JNCL. Cortical sections from wild type (WT), Cln3−/− and Tpp-1−/− mice (a,
b) or from LINCL and JNCL human cases (c) were immunostained with
Glial Fibrillary Acid Protein (GFAP) or Cluster of Differentiation 68 (CD68)
to investigate the level of reactive astrocytosis or microglial activation,
respectively. Compared to the very low level of glial activation
present in WT mice (shown at 6.5 months of age, but changes very
little over time), marked astrocytosis (a) and microglial activation
(b) was apparent in severely affected 4-month-old Tpp-1−/− mouse
sections, with hypertrophied astrocytes with intense GFAP immunostaining
and thickened processes, and morphologically transformed microglia with
intense CD68 immunostaining being observed. a In contrast, astrocytosis
appeared different in nature in the Cln3−/− cortex, and although many
astrocytes displayed intense GFAP immunoreactivity, especially in the
deeper laminae, most these astrocytes still retained many thin processes
reminiscent of protoplasmic astrocytes. Even at the end stages of the
disease (21-month-old Cln3−/− mice) very few astrocytes became fully
hypertrophied. b A similar attenuated morphological transformation of
microglial cells was also apparent in the cortex of Cln3−/− mice. Although
microglia became more intensely CD68 immunoreactive and more
swollen with increased age, many of these cells retaining long
branched processes, even in 21-month-old Cln3−/− mice. (c) Reactive
astrocytosis was observed in both human INCL and JNCL (c), but
to very different extents. In LINCL cases astrocytes were intensely
immunostained, with hypertrophied cell bodies and numerous
thickened processes. In JNCL cases GFAP immunostaining was paler
and far fewer, less hypertrophied astrocytes with thinner processes
were evident. Only a few CD68 positive microglia were observed in
JNCL cases (c), compared to the relative abundance of activated CD68
immunoreactive microglia activation present in the cortex of LINCL
cases. Scale bars = 120 μm (a, b) 20 μm in higher magnification views;
50 μm (c). Roman numerals in a, b indicate cortical laminar boundaries
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more widespread within V1 of Cln3−/− mice with disease
progression, being present in lamina II and most of lam-
inae V and VI at 12 months of age, and additionally in
lamina IV by 21 months of age. Although the intensity of
GFAP immunoreactivity progressively increased with
time, only a small proportion of these astrocytes (mostly
within lamina VI) displayed thickened processes or an
enlarged cell soma, with most retaining a protoplasmic
appearance with thin processes, even in severely affected
21 month old Cln3−/− mice. These data suggest that at
least a subset of Cln3−/− astrocytes do retain the ability to
transform morphologically, but only in a protracted man-
ner towards disease end-stage.
A similarly attenuated activation of microglia was also
evident in the cortex of Cln3−/− mice (Fig. 1b). Although
CD68 immunoreactive microglia were clearly more
darkly immunostained in V1 of Cln3−/− mice than in WT
controls at all ages examined, these microglia retained a
relatively small cell soma and numerous long thin pro-
cesses. Only in severely affected Cln3−/−mice by 21 months,
were more overtly swollen and activated microglia were
seen, and these were largely restricted to the more ventral
portion of lamina VI and V. Even then, many of these swol-
len CD68 positive cells retained long thickened processes.
This is in marked contrast to the V1 of 4-month-old Tpp-1
−/− mice that were at disease end-stage, where numerous
intensely immunostained, completely rounded, and fully ac-
tivated amoeboid microglia were evident.
Taken together, these data suggest that loss of Cln3
impairs the morphological transformation of both astro-
cytes and microglia, which is limited and only occurs late
in the disease, in more severely affected Cln3−/− mice.
Having described a relatively limited glial response in the
hippocampus of human CLN3 disease cases [90], we next
investigated whether a similar phenotype was also evident
in the primary visual cortex of CLN3 disease patient brain
autopsy material (Fig. 1c). Numerous intensely immuno-
stained GFAP positive hypertrophied astrocytes with many
thickened processes were observed in V1 of CLN2 cases.
In contrast, only a few weakly immunostained GFAP ex-
pressing astrocytes with thin processes were present in
this region of CLN3 disease cases (Fig. 1c, top row). Simi-
larly, dramatically fewer CD68 positive microglia were ob-
served in V1 of CLN3 disease cases compared with CLN2
disease cases (Fig. 1c, bottom row).
These morphological observations suggest that the
basic biology of glia, the neuronal support cells, may be
impaired in CLN3 disease. To begin investigating how
loss of CLN3 expression could influence glial cell func-
tion, we compared the properties of Cln3−/− and WT
glial cells using primary cultures of either astrocytes or
microglia, having first defined the composition of our
astrocyte (Additional file 1: Figure S1 and Additional
file 2: Figure S2) and microglial monocultures
(Additional file 3: Figure S3). One week after plating
microglial cultures showed over 99% of DAPI stained
cells expressed CD68 (99.97 ± 0.02% and 99.97 ± 0.02%
CD68 + ve in WT and Cln3−/−, respectively; with only
0.03 ± 0.02% and 0.03 ± 0.03% being GFAP + ve). One
week after plating over 98% of DAPI positive cells in
our astrocyte cultures were positive for GFAP (WT:
98.80 ± 0.28% GFAP + ve, 1.90 ± 0.17% CD68 + ve, and
0.10 ± 0.10% O4 + ve; Cln3−/−: 98.86 ± 0.10% GFAP + ve,
1.05 ± 0.13% CD68 + ve, and 0.10 ± 0.03% O4 + ve).
With subsequent time in culture an increased fraction of
DAPI stained, but GFAP negative cells were apparent in
our astrocyte cultures, especially those from WT mice
(e.g. see Fig. 3A.). However, at these later time points vir-
tually all these DAPI labelled cells immunostained posi-
tively for a second astrocyte marker glutamine synthetase
(see Additional file 2: Figure S2 for an example taken
48 h later), suggesting a dynamic down-regulation of
GFAP over time under some culture conditions. Never-
theless, a minor contamination of our astrocyte cul-
tures with ependymal or endothelial cells cannot be
excluded.
Morphological responses of Cln3−/− glia to activation are
attenuated
To determine whether the attenuated morphological
response of Cln3−/− glia observed in vivo was mimicked
in vitro, we stimulated monocultures of either microglia
and astrocytes and assessed their ability to undergo mor-
phological changes. To do this we exposed cultures to
standard inflammatory stimuli that up-regulate pathways
associated with immune and injury-related functions
[38], either the bacterial endotoxin lipopolysaccharide
(LPS) alone to activate microglia, or to LPS combined
with interferon-γ (IFN), which synergizes with the ef-
fects of LPS, to activate astrocytes [26].
We first confirmed that Cln3−/− glia were able to acti-
vate relevant downstream signaling pathways (phosphor-
ylated NF-κβ subunit p65 and phosphorylated STAT-1,
as downstream effectors of LPS and IFNγ stimulation
respectively, [22, 94]) (Additional file 4: Figure S4). Next,
to characterize the morphological transformation of
microglia, WT and Cln3−/− microglial cultures were
immunostained with CD68 at various time-points after
activation (2, 6, 12, 24, 48, 72 and 96 h), dividing these
cells according to their morphology into Type 1 (non-ac-
tivated), Type 2 cells (partly activated) and Type 3 cells
(fully activated) (see methods). Even under basal condi-
tions, CD68 immunoreactivity appeared more intense in
Cln3−/− vs. WT microglial cultures, with more rounded
cells present (Fig. 2A). Upon stimulation, microglia of
both genotypes morphologically transformed, but many
fewer Cln3−/− microglia changed shape after 24 h (Fig.
2A). When these changes were quantified (see Fig. 2B),
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there were more type 2 cells in Cln3−/− vs. WT microglial
cultures under basal conditions (Fig. 2C, compare
panels a and b), suggesting a higher level of basal activa-
tion, but a slower morphological transformation of CLN3
disease microglia. A transformation of Type 1 cells into
Type 2 cells occurred in microglial cultures of both geno-
types upon stimulation, however, Cln3−/− microglia
responded more slowly than WT microglia, with a slower
decline in the number of Type 1 cells (Fig. 2C, a, b) and a
slower increase in the number of Type 2 cells (Fig. 2C,
compare panels c and d). Until 48 h very little change was
observed in the percentage of Type 3 cells under any
condition (Fig. 2C), but by 72 h there was a dramatic
increase in the proportion of this fully activated cell type
within both WT and Cln3−/− microglial cultures under all
conditions (Fig. 2c–f ). This change was accompanied by a
reduction in the percentage of both Type 1 and Type 2,
suggesting a morphological transformation into Type 3
cells with increased time in culture.
The morphological response of astrocytes to stimulation
(LPS/INFγ treatment for 24 h or 48 h) was assessed in
GFAP immunostained cultures. Even under basal
Fig. 2 Attenuated morphological transformation of Cln3−/− microglia. The morphology of wild type (WT) and Cln3-deficient (Cln3−/−) microglia studied
under basal conditions and after stimulation with LPS was revealed by CD68 immunostaining (red). A Cultures of unstimulated WT microglia were mainly
bipolar but upon LPS stimulation for 24 h these cells rapidly changed shape. In contrast, while cultures of Cln3−/− microglia exhibited a heterogeneous
morphology and had intense immunostaining for CD68 under basal conditions these cells failed to dramatically change shape upon stimulation for 24 h.
B To quantify morphological changes over time, cells were divided into three categories: Type 1 cells (resting microglia); Type 2 cells (migrating/activated
microglia); type 3 (amoeboid activated microglia). C The transformation of type 1 cells into type 2 cells initially occurred more slowly in Cln3−/− microglial
cultures upon stimulation, with type 3 cells first appearing in cultures of both genotypes around 48 h regardless of treatment. Scale bars = 50 μm (A, B)
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conditions, untreated Cln3−/− astrocytes had a strikingly
different morphology to WT astrocytes, appearing larger
and flatter, with disrupted intermediate filaments (Fig. 3).
Upon stimulation, WTastrocytes already began to morpho-
logically transform after 24 h; changing from broad, non-
process bearing, flat cells into cells with a shrunken soma
and multiple branched processes (as described in [53]) (Fig.
3A, c arrowheads). These changes become more apparent
with time (Fig. 3A, e). In contrast, no significant morpho-
logical transformation of Cln3−/− astrocytes could be de-
tected until 48 h stimulation, when soma size began to
decrease and some cells developed processes (Fig. 3A, f).
To quantify these changes the soma size of WT and Cln3
−/− astrocytes were compared (Fig. 3B). After activation for
24 h or 48 h, the cell soma of WT astrocytes became
smaller, and this was statistically significant after 24 h
(30.5% ± 3.3 decrease). After 24 h of stimulation the soma
size of Cln3−/− astrocytes remained unchanged, but after
48 h of stimulation was not statistically different to that of
stimulated WTastrocytes (Fig. 3C).
These data demonstrate that Cln3−/− astrocytes and
microglia are attenuated in their ability to change their
morphology upon stimulation, suggesting that these cells
retain at least some of their in vivo disease characteris-
tics when cultured.
Cln3−/− astrocytes, but not Cln3−/− microglia, have a disrupted
cytoskeleton
Since morphological changes require cytoskeletal rear-
rangements, and GFAP immunostaining suggested that
intermediate filament organization was perturbed in
Cln3−/− astrocytes (Fig. 3A), we also immunostained as-
trocytes for α- and β-tubulin to visualize microtubules
and with phalloidin to visualize F-actin filaments and a
similar cytoskeletal analysis was performed with microglia.
Both intermediate filaments and F-actin filaments ap-
peared less defined and highly disorganized in Cln3−/−
vs. WT astrocytes (Fig. 4, a, b for GFAP, and c, d for F-
actin, examples marked with arrowheads). Most Cln3−/−
astrocytes lacked F-actin filaments that spanned the cell
body, a common morphological feature of cultured WT
astrocytes (Fig. 4c, d). However, the α- and β-
microtubular organization of WT and Cln3−/− astrocytes
appeared similar (Fig. 4, e, f and g, h, examples marked
with arrows). These data reveal that enlarged Cln3−/−-
astrocytes have an abnormally organized actin and inter-
mediate filament cytoskeleton, whilst their microtubule
organization appears normal. No overt changes were ob-
served in the cytoskeletal organization of Cln3−/−micro-
glia (data not shown).
Cln3−/− glia show altered protein secretion profiles
The secretion of soluble factors is a key feature of both
microglia and astrocytes under both physiological and
Fig. 3 Attenuated morphological transformation of Cln3−/−
astrocytes. The morphology of wild type (WT) and Cln3-deficient
(Cln3−/−) astrocytes was studied under basal conditions and after
stimulation with LPS/IFNγ for 24 or 48 h by immunostaining with
GFAP (red in A, green in B). DAPI (blue) was used to visualize all
nuclei. A WT astrocytes changed their morphology dramatically after
a 24 h exposure to LPS/INFγ to display characteristic branched
processes (arrowheads) and these changes became enhanced over
time. In contrast Cln3−/− astrocytes remained relatively
morphologically unchanged after 24 h of stimulation remaining as
large flat cells with no processes, but showed morphological
changes after 48 h activation. B ImageJ was used to quantify
astrocyte cell body size under all experimental conditions by
drawing around the soma of GFAP positive cells (dashed lines, with
contained area shaded red). C The mean cell soma sizes were
determined by quantifying 10 random fields per coverslip and a
minimum of two coverslips per experiment. Scale bar = 50 μm
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pathological conditions [51], therefore we compared the
secretion profiles of WT and Cln3−/− glia under basal
conditions and after stimulation.
Cln3−/− and WT microglia did not display any differ-
ences in the levels of factors secreted under basal condi-
tions (data not shown), but five proteins were secreted at
significantly lower levels by Cln3−/− microglia upon LPS
stimulation (Fig. 5). These proteins included three chemo-
kines (MIP-1-γ, MIP-2 and RANTES), a glycoprotein
(vWF) and a matrix metalloproteinase (MMP-9). These
data indicate that Cln3−/− microglia retain their capacity
to secrete the majority of soluble factors into their envir-
onment. Equally, we observed no difference in the
phagocytic properties of Cln3−/− microglia grown under
basal conditions or after stimulation (data not shown).
Under basal conditions there was no significant difference
between WT and Cln3−/− astrocytes in the secretion pat-
tern of the majority of proteins analyzed (Additional file 5:
Table S1). However, upon exposure to LPS/IFN-γ a broad
range of secreted proteins were detected at signifi-
cantly reduced levels in Cln3−/− astrocyte supernatants
(Additional file 5: Table S2). Indeed, out of the 59
screened factors none (at 6 h), 19 (at 24 h) and 42 (at
72 h) factors were secreted at significantly lower levels
by Cln3−/− astrocytes compared to WT astrocytes upon
activation (Additional file 5: Table S1 and S2). These in-
cluded the reduced secretion of several mitogens (M-CSF,
IL-3, FGF2, GM-CSF, FGF-9, TPO and IL-5), chemokines
(Eotaxin, MIP1α, MCP-3, MCP-1, KC/GROα, MIP-3α,
MIP-2, IP-10, RANTES, MDC, MCP-5, MIP-1γ, GCP-2
and MIP-1β), anti- and pro-inflammatory cytokines (IL-
17α, IL-6, IL-12p70, IL-1α, TNFα, IL-1β, IL-10, IL-2). Fur-
thermore, these cells also showed an impaired ability to
secrete a range of proteins shown to have neuroprotective
properties: IL-6 [95], IL-3 [101], GM-CSF [55], IL-10 [7],
LIF [57], MCP-1 and RANTES [15].
There were however exceptions to this pattern of al-
tered protein secretion. Two chemokines, macrophage
inflammatory protein-1γ (MIP-1γ) and granulocyte
chemotactic protein 2 (GCP-2) were both secreted sig-
nificantly less by Cln3−/− astrocytes under basal condi-
tions, while one protein, tissue factor (TF), was secreted
more by Cln3−/− astrocytes under basal conditions. In
contrast fibrinogen and the mitogen CRP were secreted
significantly more by Cln3−/− astrocytes upon stimula-
tion. Examples of astrocyte secretion profiles for specific
proteins are shown in Fig. 6.
Altered glutathione handling by Cln3−/− astrocytes
The altered secretion profile of Cln3−/− astrocytes led us
to consider that these cells may also fail in their antioxi-
dant support of neurons, particularly in their ability to
secrete glutathione (GSH), one of the brain’s most im-
portant neuroprotective factors [31, 78].
To analyze the ability of astrocytes to make and secrete
GSH, cultures were washed, lysed and the intracellular
levels of the reduced (functional) form of GSH measured.
Under basal conditions, no significant differences in GSH
levels were detected between WT and Cln3−/− cultures
(Fig. 7a). However, following stimulation the intracellular
levels of reduced GSH decreased significantly in WT
cultures (56.3 ± 12.0% reduction after 24 h exposure,
59.9 ± 12.6% reduction after 48 h, Fig. 7a), but were mark-
edly increased in Cln3−/− cultures (63 ± 33.6% increase
after 24 h, 28.1 ± 19.3% increase after 48 h, Fig. 7a). Thus,
intracellular GSH levels in LPS/IFNγ treated WT astro-
cytes were significantly lower than in LPS/IFNγ treated
Fig. 4 Cln3−/− astrocytes have a disrupted cytoskeleton. The cytoskeletal
organization of wild type (WT) and Cln3-deficient (Cln3−/−) astrocytes was
determined by immunostaining with GFAP (red in a, b) to visualize
intermediate filaments, phalloidin to visualize F-actin (red in c, d),
and α- or β-tubulin to visualize microtubules (green in e, f and in
g, h, respectively). DAPI was used to visualize nuclei (blue). WT
astrocytes had a well-organized intermediate filament, F-actin and
microtubule cytoskeleton (arrowheads in a, c, e, g), while Cln3−/−
astrocytes had a highly disrupted intermediate filament and F-actin
cytoskeleton (arrowheads in b and d) but their microtubule structure
appeared normal (arrowheads in f and h). The cell body size of Cln3−/−
astrocytes appeared larger than that of WT astrocytes. Scale bar = 25 μm
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Cln3−/− astrocytes after 24 (59.6 ± 12.2% decrease in WT
vs. Cln3−/−) and 48 h (51.9 ± 14.3% decrease in WT vs.
Cln3−/−). These data suggest a failure of Cln3−/− astrocytes
to secrete GSH, consistent with the observation that
significantly higher levels of extracellular GSH could be
detected in the medium from WT vs. Cln3−/− astrocytes
after stimulation (Fig. 7b).
Since the method described above only measures the
reduced form of glutathione, it is conceivable that these
results could be explained by an opposing change in the
level of oxidized glutathione (GSSG). This possibility
was excluded by indirectly measuring intracellular GSSG
levels by converting GSSG to GSH using glutathione
reductase (GR). Subsequent HPLC analysis revealed no
measurable difference between the intracellular levels of
GSH and total glutathione (after GR treatment) in any
of these samples, suggesting that all the intracellular
glutathione in both WT and Cln3−/− astrocytes is present
in the reduced form (data not shown).
The actin cytoskeleton is important for exocytosis in
astrocytes [70], and it appears abnormally organized in
Cln3−/− astrocytes (Fig. 3A). Therefore, the possible con-
nection between the disrupted actin cytoskeleton and
impaired glutathione secretion was examined by treating
WT astrocytes with cytochalasin D (1uM for 30 min be-
fore the 8 h measurement period) to inhibit the
polymerization of actin. This resulted in a significant reduc-
tion (50.1 ± 12.7%) in the levels of extracellular glutathione
in LPS/IFNγ treated WT astrocytes (Additional file 6:
Figure S5). Thus, a normal actin cytoskeleton is essen-
tial for glutathione secretion by astrocytes.
Since the defects in Cln3−/− astrocytes appeared more
profound than those in microglial cells, and the cytoskeletal
disruption observed in these cells could impact many of
their functions, we investigated whether Cln3−/− astrocytes
could perform other key tasks effectively.
An impaired ability of Cln3−/− astrocytes to migrate, clear
glutamate and signal via Ca2+
Slower migration of Cln3−/− astrocytes
Astrocyte migration is associated with local inflamma-
tion [17] and requires cytoskeletal rearrangements, rais-
ing the likelihood that this process may be impaired in
Cln3−/− astrocytes. To test this possibility, an Essen
Wound-maker was used to create a cell-free area in con-
fluent cultures of WT and Cln3−/− astrocytes, and the
Fig. 5 Altered protein secretion profiles of Cln3−/− microglia. Secreted protein levels were quantified from supernatants collected from WT and
Cln3−/− microglial cultures grown under basal conditions, or after stimulation with LPS. Following quantitative analysis of 59 soluble factors, 5
were found to be secreted at significantly lower levels by Cln3-deficient (Cln3−/−) microglia over time in culture compared to wild type (WT)
microglial cultures. These included the chemokines MIP-1-γ, MIP-2 and RANTES, the glycoprotein vWF, and the matrix metalloproteinase MMP-9
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ability of the cells to migrate and fill this space assessed.
WT astrocytes migrated into the cell free area rapidly
and nearly closed the gap within 24 h (Fig. 8a). The dis-
tance covered by Cln3−/− astrocytes over this same time
was significantly reduced (Fig. 8b). The rate of migration
was significantly decreased in the absence of CLN3 (WT
5.3 ± 0.6 μm/h vs. 2.3 ± 0.6 μm/h for Cln3−/− astrocytes)
(Fig. 8c), and WT astrocytes migrated further and faster
than Cln3−/− astrocytes.
Cln3−/− astrocytes show impaired glutamate clearance
A feature of JNCL pathogenesis is an elevated level of
glutamate in the brains of Cln3−/− mice [65]. A glutam-
ate assay kit revealed that Cln3−/− astrocytes take-up
significantly less glutamate from the medium than WT
astrocytes (48.0% ± 14.0% reduction in glutamate uptake,
Fig. 9), suggesting that Cln3−/− astrocytes may not be
able to scavenge excess extracellular glutamate as effect-
ively as WT astrocytes.
Cln3−/− astrocytes do not form a synchronized calcium wave
Calcium signaling forms the basis for astrocyte-astrocyte
and astrocyte-neuron communication in the CNS [103].
Indeed, Ca2+ is exploited by astrocytes as an intercellular
signal for long distance communication through func-
tionally connected astrocyte networks. This synchronous
calcium wave is propagated via gap junctions and has
the potential to coordinate neurotransmitter release at
Fig. 6 Cln3−/− astrocytes show differences in their ability to secrete proteins. Secreted protein levels were quantified from supernatants collected
from wild type (WT) and Cln3-deficient (Cln3−/−) astrocyte cultures grown under basal conditions or after stimulation with LPS/IFNγ. Examples of
chemokines (a), neuroprotective factors (b) and proteins secreted at elevated levels by Cln3−/− astrocytes following activation (c), are shown. a
Cln3−/− astrocytes secreted significantly less MIP-1ß, MIP-1α and MCP-1 when treated with LPS/IFNγ than did WT astrocytes. There was no significant
difference between untreated WT and Cln3−/− samples. b Cln3−/− astrocytes secreted significantly less IL-6, TNF-α and VEGF upon activation than did
WT astrocytes. There was no significant difference between untreated samples. c Cln3−/− astrocytes secreted significantly more CRP and IgA after 24 h
exposure to LPS/IFNγ, no such change was observed in WT astrocytes
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all synapses within the astrocyte syncytium [92]. To ex-
plore the ability of WT and Cln3−/− astrocytes to generate
a calcium wave in response to ATP [46], these cells were
plated on PDL-coated 25 mm coverslips at high density so
that they formed a continuous sheet. Calcium measure-
ments were obtained after loading cells with the ratio-
metric and sensitive calcium indicator, Fura-2 AM, with
results obtained over the first 20 min presented (Fig. 10).
A calcium wave, which initiated approximately 6 min
after the start of the recordings, was obvious in high-
density WT astrocyte cultures (Fig. 10, yellow bar). This
synchronized, [Ca2+]I elevation among WT astrocytes
had a large amplitude (from 150% up to nearly 250%
increase compared to baseline), and a clear plateau
phase indicating prolonged high intracellular calcium
levels after the initiation of the wave (Fig. 10). In sheet-
forming Cln3−/− astrocyte cultures, however, no such
synchronized [Ca2+]I elevation was observed (Fig. 10).
Instead, these Cln3−/− astrocytes exhibited sporadic calcium
oscillations that did not propagate as an intercellular
calcium wave. This suggests that the communication
between Cln3−/− astrocytes may be severely compromised,
and this in turn could impact on the control of
neurotransmission.
Altered Cln3−/− neuronal morphology
We next investigated the in vitro phenotypes of Cln3-de-
ficient cortical neurons. In the absence of any overt ef-
fect on intrinsic neuronal survival this analysis initially
focused upon soma size, and neurite complexity.
Qualitatively, the distribution of MAP2 immunoreactiv-
ity appeared different in neurons of different genotypes,
appearing to be more intense within the apparently
smaller cell soma of Cln3−/− neurons compared to the
more even distribution within the soma and processes of
WT neurons (Fig. 11A). Cell area measurements revealed
Cln3−/− neuron soma to be significantly smaller than WT
cells (Fig. 11B), and their neurite complexity was altered
(Fig. 11C). Although Cln3−/− neurons had slightly more
branching points than WT neurons, these differences
were not statistically significant. However, the length of
the longest primary neurite was significantly shorter in
Cln3−/− neurons (Fig. 11C, e), which also displayed a sig-
nificantly shorter network of primary neurites (Fig. 11C, f).
JNCL glia are detrimental to neuronal health
The finding that Cln3−/−astrocytes, and to a lesser extent
microglia, have a compromised biology suggested that
Cln3−/− glia could potentially have a detrimental effect
on neuronal health. To test this hypothesis, primary cor-
tical WT or Cln3−/− astrocytes and microglia were
seeded on top of WT or Cln3−/− primary cortical neur-
onal cultures. Glia in these co-cultures were not exposed
to LPS or LPS/IFNγ. As a readout of neuronal health we
analyzed the same neuronal phenotypes defined above,
and assessed if there were any impact upon neuronal
survival, and neurite complexity in these co-cultures.
Co-cultures were monitored for 7 days, and over this
time, those composed of WT mixed glia and WT neu-
rons remained healthy, with very few dying cells present
(Fig. 12A, panel a). However, from day 2 onwards MAP2
immunoreactivity in processes of WT neurons grown
with Cln3−/− glia became increasingly punctate, suggesting
compromised neuronal health, and by day 7 many dying
neurons with red nuclei were observed (Fig. 12A, panel b).
The morphology of the surviving WT neurons was also
dramatically altered, showing a reduction in soma size and
neurite complexity (Additional file 6: Figure S5). The
co-culture combination of Cln3−/− neurons with Cln3−/−
glia was the most detrimental for neuronal health, since
by day 7 most of the Cln3−/− neurons in these co-cultures
were either dead (Fig. 12A, panel d), or appeared se-
verely compromised, as judged by their morphology
(Additional file 7: Figure S6). Interestingly, WT glia had
Fig. 7 Cln3−/− astrocytes fail to secrete glutathione. Wild type (WT)
and Cln3-deficient (Cln3−/−) primary cortical astrocytes were analyzed
for their ability to synthesize and secrete reduced glutathione (GSH).
a Reverse phase HPLC was used to measure the intracellular levels
of GSH in WT and Cln3−/− astrocytes treated with LPS/IFNγ for 24 or
48 h, or from untreated samples. The GSH levels in each sample
were normalized to the total amount of protein in that sample and
results presented in nmol/mg of protein. Additionally, these results
were normalized to untreated WT astrocyte GSH levels in each
experiment. LPS/IFNγ stimulation caused a significant decrease in
the intracellular levels of GSH in WT astrocytes but not in Cln3−/−
astrocytes. b The GSH-Glo kit was used to measure the total amount
of GSH secreted into the medium over an 8 h period by cultures of
untreated and LPS/IFNγ treated WT and Cln3−/− astrocytes. TCEP
(12uM) was used to convert the oxidised form of glutathione (GSSH)
to GSH to measure the total amount of GSH in each sample. These
results were normalized to released %LDH from total LDH. LPS/IFNγ
treated Cln3−/− astrocytes secreted significantly reduced levels of
GSH compared to LPS/IFNγ treated WT astrocytes
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a positive influence on both the survival and morph-
ology of Cln3−/− neurons (Fig. 12A, panel c).
In these co-cultures, we observed that in the presence of
Cln3−/− neurons, Cln3−/− astrocytes had smaller cell bodies
and longer, more numerous processes (reminiscent of acti-
vated astrocytes in culture), when compared to Cln3−/−-
astrocytes grown with WT neurons (Additional file 8:
Figure S7). No such morphological change was evident
when Cln3−/− neurons were co-cultured with WT glia,
suggesting that Cln3−/− astrocytes are more sensitive to
the environment than their WT counterparts. Under all
culture conditions the morphology of microglia were
heterogeneous with some cells bearing processes and
others being fully rounded (data not shown).
These morphological findings correlated well with
measurements of released LDH from the different co-
cultures (Fig. 12B). The lowest LDH levels were ob-
served when WT glia and neurons were co-cultured, but
these levels increased dramatically when Cln3−/− glia
were co-cultured with WT or Cln3−/− neurons (Fig. 12B).
However, when Cln3−/−neurons were co-cultured with
WT, rather than Cln3−/− glia, a lower level of LDH re-
lease was observed, possibly due to the supportive influ-
ence of the WT cells (Fig. 12B). As might be expected,
there was significantly more LDH released in Cln3−/−
glia/Cln3−/− neuron co-cultures than in WT glia/WT
neuron co-cultures (Fig. 12B).
These results suggest that Cln3−/− glia are detrimental
to the health of both WT and Cln3−/− neurons, with
Cln3−/− neurons being the most vulnerable. In contrast,
WT glia appeared to have a positive influence on Cln3
−/−neurons, not just on survival, but also upon neurite
complexity.
Discussion
This study highlights the attenuated morphological
transformation of astrocytes and microglia in both human
and murine CLN3 disease. From studying cultured Cln3−/−
astrocytes and microglia we have provided further support
that their biology is impaired (see 16 [99]). Although
Fig. 9 Glutamate clearance is altered in Cln3−/− astrocytes. The
ability of wild type (WT) and Cln3-deficient (Cln3−/−) astrocytes to
clear glutamate from the medium was assessed using a Glutamate
Assay Kit. WT and Cln3−/− astrocytes were incubated with 2 mM
glutamate for 2 h, and wells without astrocytes were used as
controls. The glutamate remaining in the medium was quantified
and normalized to the total amount of protein, and the glutamate
uptake values of Cln3−/− astrocytes were normalized to those of WT
astrocyte samples. Cln3−/− astrocytes took up significantly less
glutamate than did WT astrocytes over the 2 h period
Fig. 8 Cln3−/− Astrocytes have a migration defect. Wild type (WT) and Cln3-deficient (Cln3−/−) primary cortical astrocytes were plated on Essen
Image Lock 24 well plates, grown to confluence then scratched using an Essen wound maker. a Representative pictures of the wound at three
time points. b The distance migrated by WT and Cln3−/− astrocytes every 4 h was calculated by comparing wound widths between the start and
the different time points. WT astrocytes migrated significantly further than did Cln3−/− astrocytes. c The rate of migration was measured by
calculating the distance migrated by these cells/h. Cln3−/− astrocytes migrated significantly slower than WT astrocytes. In each experiment three
wound widths were measured per well and three wells quantified per experiment
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specific microglial defects are certainly evident, astrocytes
appear more severely affected, and these astrocyte defects
may be due to the cytoskeletal abnormalities they display.
Most importantly, we show that while Cln3−/− neurons are
themselves compromised, the combined presence of Cln3
−/− astrocytes and microglia exacerbate these phenotypes
and have a detrimental effect on neuronal organization and
health. Taken together, these data provide novel informa-
tion that these glial cells exert a negative influence upon
neurons and may directly influence neurodegeneration in
CLN3 disease.
Defects in glial biology could underlie components of
CLN3 disease pathogenesis
Despite concerted efforts, the normal function of CLN3
remains poorly understood and it is unclear how its defi-
ciency relates to cellular dysfunction, including that of
astrocytes or microglia. Despite microglia accumulating
large amounts of storage material, which is also present
in astrocytes, the current view is that it is not the accu-
mulation of storage material per se that directly causes
cellular dysfunction and death. Instead it appears that
other, as yet unknown, consequences of Cln3-deficiency
are responsible. Our data suggest that these negative
consequences of Cln3-deficiency are also evident in glia,
rather than being confined to neurons, and it will be
important to gain in vivo correlates of the data we have
found in tissue culture.
Nevertheless, all the biological defects we found associ-
ated with cultured Cln3−/− astrocytes and microglia can
plausibly be linked to known features of CLN3 disease
pathogenesis, including the potential involvement of
glutamate mediated excitotoxicity and oxidative stress. In-
deed, although in vitro systems do not necessarily accur-
ately reflect the in vivo situation, a series of similarities
between our tissue culture observations and other reports
exist. For example, the attenuated ability of Cln3−/− glia to
respond morphologically to stimulation is also evident in
the Cln3−/− mouse brain in vivo (Fig. 1, and [68, 69]), and
a comparatively lower level of glial activation is evident in
human CLN3 disease ([90], this study). This is in marked
contrast to the robust glial activation and morphological
Fig. 10 Cln3−/− Astrocytes Show Altered Calcium Signalling. Recordings of Fura-2 fluorescence were made from high density, sheet forming
cultures of wild type (WT) and Cln3-deficient (Cln3−/−) astrocytes grown under basal conditions over a period of 30-45 min, from which the first
20 min are shown. The figure illustrates changes in [Ca2+]I in three randomly selected WT and Cln3
−/− astrocytes. In response to treatment with
100 μM ATP, a propagating [Ca2+]I wave was generated by WT astrocytes (marked with yellow bar). This synchronized [Ca
2+]I wave had a large
amplitude, and a prolonged plateau persisting for several minutes after initiation. The Cln3−/− astrocytes did not exhibit any propagating calcium
waves, instead, Cln3−/− astrocytes had non-synchronized, spontaneous [Ca2+]I elevations. Data is presented as 340 nm/380 nm ratio, which directly
correlates with the change in intracellular free Ca2+ levels
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transformation observed in all other forms of murine
[24, 40, 47, 59, 64, 77, 93], ovine [61], or human
NCL [90].
The impaired ability of Cln3−/− astrocytes to take up
extracellular glutamate is consistent with the reduced
expression of the glutamate receptor EAA2 in human
CLN3 brain tissue [36], the reduced GLAST and glutamine
synthetase levels evident in Cln3Δex7/8 mice [16], and
presynaptic elevation of glutamate in Cln3−/− mice [20].
Furthermore, neurons in these mice appear particularly
vulnerable to AMPA-and NMDA-receptor stimulation
[32, 43], perhaps because of excitotoxicity due to these
Fig. 11 Cln3−/− cortical neurons are small and have shortened processes. The morphology of primary cortical wild type (WT) and Cln3-deficient
(Cln3−/−) neurons was compared quantitatively using ImageJ after cultures were fixed and immunostained with MAP2. A MAP2 expressing WT
and Cln3−/− cortical neurons showing that, unlike in WT cells, MAP2 immunoreactivity is not evenly distributed between the cell soma and
processes in Cln3−/− neurons. B Quantification of cell soma size revealed that WT neurons have a significantly bigger cell soma than Cln3−/−
neurons. C Quantitative assessment of neurite complexity, (a) schematic illustration of neurite branching, showing primary neurites (1) originating
directly from the cell body, secondary neurites (2) originating from primary neurites, and tertiary neurites (3) originating from secondary neurites.
The length of each of the primary neurites was analyzed, and the sum of the length of all of these neurites calculated. (b, c and d the number of
each type of neurite did not differ between WT and Cln3−/− neurons. e WT neurons had a longer primary neurite, and (f) an increased total
length of the primary neurites compared to Cln3−/− neurons. Data in (b) and (c) represent mean ± SEM from approximately 40 individual cells
analyzed in each experiment. This experiment was repeated three times. The scale bar in (A) is 20 μm
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elevated levels of glutamate, and different classes of
glutamate antagonists provide some therapeutic benefit
in Cln3−/− mice [41–44].
Another pivotal astrocyte function is the synthesis and
secretion of the anti-oxidant glutathione (GSH) that
plays a crucial role in protecting neurons against oxidative
stress [31, 33]. Our data reveal that Cln3−/− astrocytes can
still make, but fail to secrete, glutathione. Indeed,
Drosophila lacking CLN3 function are hypersensitive
to oxidative stress [89], and oxidative damage has also
been reported in both mouse [6] and human CLN3
disease [3].
Our calcium signaling studies revealed that Cln3−/− as-
trocytes fail to generate a calcium wave after exposure to
ATP, providing further evidence that intercellular signal-
ing between CLN3 astrocytes may be compromised [16],
and it will be important to study calcium signaling in
acute slice preparations. This could impact upon the
control of neurotransmission in the JNCL brain and
perhaps contribute to the seizure activity observed in
this disease [58, 67, 88].
All these functional problems associated with Cln3−/−
astrocytes and some of the phenotypes seen in vivo may
at least partially be explained by their disrupted cytoskel-
eton, since expression of glutamate receptors at the cell
surface [48], calcium signaling among astrocytes [27]
and secretion by astrocytes [45] have all been shown to
require a functional actin cytoskeleton. Indeed, the altered
shape of Cln3−/− astrocytes, along with the difficulties they
exhibit in changing their morphology in vivo and in our
culture, may plausibly results from their disrupted cyto-
skeleton and it will be important to study this in more
detail and determine their importance in vivo. How these
defects in the cytoskeleton are related to Cln3-deficiency
is unclear, but a functional interaction of CLN3 with non-
muscle myosin-IIB has been reported [34], and a migra-
tion defect in Cln3−/− mouse embryonic fibroblasts that is
consistent with our novel data for the impaired migration
of Cln3−/− astrocytes.
Alteration in protein secretion could impair cell-cell
interactions
The protein secretion profiles of both Cln3−/− astrocytes
and microglia was altered following activation, with as-
trocytes being more severely affected, showing signifi-
cantly reduced levels of secretion of a range of proteins
(Additional file 5: Tables S1 and S2). Our data are con-
sistent with the reported evidence that LPS stimulation
also results in a lower level of cytokine secretion by
microglia derived from Cln3Δex7/8 mice bearing the 1 kb
deletion that is present in most CLN3 disease cases [99].
Intriguingly, these authors suggest that the responses of
Cln3-deficient microglia are stimulus-dependent, with
ceramide or neuronal cell lysates resulting in an in-
creased inflammasome activation and expression of a
wide array of proinflammatory cytokines and chemo-
kines [99]. However, it should be borne in mind that
these authors used Cln3Δex7/8 ‘knock-in’ mice rather
than the Cln3−/− mice used in our study, and this may
influence the different phenotypes observed.
The biological significance of our data showing altered
secretion profiles of Cln3-deficient glia remains unclear,
but the downstream effects are likely to be complex
given the multiple and possibly synergistic effects of se-
creted proteins on different cell types under both physio-
logical and pathological situations [1, 19, 73, 74, 83]. It is
also important to emphasize that what we have detected
in vitro may not reflect the in vivo situation. Nevertheless,
our data raise the possibility that cell-cell communication
via secreted factors may potentially be perturbed in the
CLN3 disease brain. In addition, many of the neuroprotec-
tive proteins routinely secreted by WT astrocytes after ac-
tivation [15, 30, 57, 76, 95, 100], are also significantly
Fig. 12 Cln3−/− cells negatively impact WT cells. P0 cortical wild type
(WT) and Cln3-deficient (Cln3−/−) neuronal cultures were combined
with either WT or Cln3−/− mixed glia cultures to study the impact of
these glial cells on neuronal health. A After 7 days of co-culture, WT
co-cultures were healthy (a) but Cln3−/− mixed glia appeared to
have a detrimental effect when cultured with both WT (b) and
Cln3−/− neurons (d) with the latter being more dramatically affected.
When WT mixed glia were co-cultured with Cln3−/− neurons, neuronal
survival improved. B Significantly less LDH released was observed in
WT neuron/WT mixed glia co-cultures compared to Cln3−/− neuron/
Cln3−/− mixed glia co-cultures. Scale bar in (A) = 20 μm
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reduced in cultures of activated Cln3−/− astrocytes, with
two of these proteins (MCP-1 and RANTES) also being
secreted at significantly lower levels by Cln3−/− microglia.
The reduced expression of IL-6, RANTES and MCP-1,
which can protect neurons against NMDA receptor-
mediated excitotoxicity, may be especially relevant given
the increased sensitivity of Cln3-deficient neurons to
AMPA receptor-mediated excitoxicity [43, 65]. Thus, de-
fects in glial-glial and glial-neuronal interactions have the
potential to have a significant impact on neuronal health
in CLN3 disease, a suggestion that prompted us to grow
mixed glial co-cultures with neurons.
Until in vivo data regarding the relative levels of chemo-
kines and cytokines become available, our in vitro data
demonstrating altered secretion levels should be interpreted
with caution, especially as these data come from pharmaco-
logically stimulated cultures. However, the reduction in
chemokine secretion by stimulated Cln3−/− glia in culture
may also have a detrimental effect on the recruitment of
microglia to sites of inflammation [72, 81], and partly ex-
plain the limited infiltration of monocytes and lymphocytes
in CLN3 disease [50]. This reduced chemokine expression
may also be associated with the attenuated microglial acti-
vation observed in vivo ([68, 69, 90], this study). Conversely,
Cln3−/− astrocytes showed a reduced ability to secrete anti-
inflammatory cytokines, such as IL-4, IL-10 and IL-2, which
could also prove harmful. Both genetic and pharmaceutical
approaches to attenuate the adaptive immune response
have been shown to result in a significant improvement in
the pathology of Cln3−/− mice [80].
Cln3−/− glia are detrimental to neuronal health
Defects in glial biology have been associated with neuronal
dysfunction and loss in many neurodegenerative diseases,
see [28, 29, 66, 75, 85]. Both positive and negative roles for
astrocytes have been proposed, and recently, more active
roles for astrocytes and microglia in directly influencing
neuron survival have been postulated [49]. Using a co-
culture approach, we have shown here that Cln3−/− astro-
cytes and microglia can indeed influence neuronal health,
affecting the size and neurite complexity of both WT and
Cln3−/− neurons, but also causing the death of the latter,
which appear to be inherently compromised by Cln3
deficiency. From our data it is not clear whether it is
the Cln3−/− astrocytes or microglia, or a combination
of both cell types that negatively influence neuronal
heath. It has been suggested that astrocytes can be primed
by microglia to become toxic to neurons [49], and it will be
important to determine if similar mechanisms operate in
CLN3 disease, especially in an in vivo context. However, it
is apparent that despite any overt intrinsic survival defect in
these short-term cultures, Cln3−/− neurons appeared to be
compromised in terms of their morphology, and it will be
important to investigate their functional status.
In other lysosomal storage disorders, introducing
astrocyte-specific gene mutations is sufficient to harm
neurons [21, 28], and correcting these defects is benefi-
cial [102]. In our studies co-culturing Cln3−/− neurons
with healthy glia improved many of their morphological
defects, and resulted in an increase in their survival,
suggesting that healthy glia appear to have a neuroprotec-
tive effect. This is in marked contrast to the apparently
negative influence of Cln3−/−glia upon both healthy and
mutant neurons. It remains to be seen how accurately our
data from cultures reflect the in vivo situation, and for this
reason we have generated cell-type specific mutant mice
in which we can inactivate Cln3 in defined cell types in
our future studies. Nevertheless, our data from this in
vitro study suggests that therapies that target glia in
addition to neurons may be an important step forward in
treating this devastating disease.
Conclusion
In summary, this study has provided evidence that both
astrocytes and microglia derived from Cln3-deficient
mice are dysfunctional, and this may contribute to dir-
ectly harming neurons in this disorder. It will be import-
ant to investigate the underlying mechanisms and the
extent of pathological involvement of each cell type in
vivo. Given the close association between glial activation
and neuron loss in these disorders, it will be important
to determine whether glia also contribute to neuron loss
in the other forms of NCL. This will information will be
crucial for determining whether strategies that target glia
will be of therapeutic value.
Additional files
Additional file 1: Figure S1. Composition of Astrocyte Cultures.
Primary cortical astrocyte cultures generated from P1–2 wild type (WT)
and Cln3-deficient (Cln3−/−) mice were grown for one week after the
addition of Ara C, and in this example stimulated for a further 48 h
before being immunostained with CD68 to identify microglia, O4 to
identify oligodendrocytes, MAP2 together with NeuN to identify neurons
and GFAP to identify astrocytes. DAPI was used to visualize all nuclei. WT
and Cln3−/− astrocyte cultures contained few microglia or
oligodendrocytes (A) and no neurons (B), and the vast majority of cells in
Cln3−/− astrocyte cultures were GFAP-expressing astrocytes (C), with a
higher proportion of DAPI + ve cells showing much weaker or no GFAP
immunostaining in WT astrocyte cultures. Scale bar in (A) and
(C) = 50 μm, and in (B) = 20 μm. (TIFF 13274 kb)
Additional file 2: Figure S2. Astrocyte Cultures stained with Glutamine
Synthetase. Since GFAP expression can be down-regulated by astrocytes
in culture, we also immunostained a parallel series of primary cortical
astrocyte cultures from P1–2 wild type (WT) and Cln3-deficient (Cln3−/−)
mice with glutamine synthetase as an additional marker of astrocyte
phenotype, after an additional 48 h in culture. DAPI was used to visualize
all nuclei. Virtually all the DAPI stained cells (blue) were also immunoreactive
for glutamine synthetase (red) in both WT and Cln3−/− cultures, and this was
quantified as being 99.71 ± 0.15% (WT) and 99.29 ± 0.21% (Cln3−/−) of the
DAPI stained cells, respectively. Scale bar = 20 μm. (TIFF 2129 kb)
Additional file 3: Figure S3. Composition of Microglial Cultures.
Primary cortical microglial cultures generated from P2–4 wild type (WT)
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and Cln3-deficient (Cln3−/−) mice were immunostained with CD68 to
identify microglia, O4 to identify oligodendrocytes, TuJ1 to identify neurons
and GFAP to identify astrocytes. DAPI was used to visualize all nuclei.
Practically all cells were CD68 expressing microglial cells (A), with virtually no
cells expressing GFAP or O4 (B). Scale bar = 20 μm. (TIFF 8572 kb)
Additional file 4: Figure S4. LPS and INFγ induced signaling is not
altered in Cln3−/− glia. Wild type (WT) and Cln3-deficient (Cln3−/−)
astrocytes were immunostained with GFAP and microglia with CD68.
DAPI was used to visualize all nuclei. Few WT or Cln3−/− glia with nuclear-
located P-p65 (A, C) and WT or Cln3−/− astrocytes with nuclear-located P-
STAT1 (B) were observed under basal conditions, while the vast
majority of both WT and Cln3−/− glia had P-STAT1 (B) and/or P-p65 (A,
C) expressed in the nucleus upon stimulation. The percentage of cells
expressing P-STAT1 and/or P-p65 in the nucleus was determined by
counting 5 random fields per coverslip and a minimum of three
coverslips per experiment. The means ±SEM shown are from three
separate experiments. (TIFF 11278 kb)
Additional file 5: Table S1. Protein secretion profile of WT and Cln3−/−
astrocytes under basal conditions. Differences between levels of secreted
proteins in supernatants collected after 6 h, 24 h and 72 h from Cln3
−/−and WT astrocyte cultures grown under basal conditions. Data
presented as % change (values from Cln3−/− astrocyte samples
compared to corresponding WT astrocyte values) ± SEM from three
biological replicates. (−) indicates proteins whose levels were below
quantifiable detection levels. Table S2. Protein secretion profile of WT
and Cln3−/− astrocytes after stimulation. Differences between levels of
secreted proteins in supernatants collected from Cln3−/− and WT
astrocytes after activation with LPS/IFNγ for 6 h, 24 h and 72 h. Data
presented as % change (Cln3−/− astrocyte sample values compared to
corresponding WT astrocyte values) ± SEM from three biological
replicates. (−) indicates proteins whose levels were below quantifiable
detection levels. (PDF 676 kb)
Additional file 6: Figure S5. An intact actin cytoskeleton is essential for
glutathione secretion. To study the importance of the actin cytoskeleton
for GSH secretion in astrocytes Cytochalasin D (1uM) was added to wild
type (WT) astrocytes for 30 min prior to the start of the 8 h period over
which the accumulation of secreted GSH in the medium was measured.
Cells were then fixed and the actin cytoskeleton visualized with phalloidin.
DAPI was used to visualize all nuclei. (A) Cytochalasin D clearly disrupted the
F-actin filament organization in WT astrocytes. (B) Perturbing actin cytoskeletal
polymerization significantly inhibited GSH secretion by WT astrocytes. Scale
bar in (A) = 10 um. (TIFF 13687 kb)
Additional file 7: Figure S6. Cln3−/− mixed glia negatively impact
neuronal morphology. Representative images of MAP2 expressing Wild
type (WT) and Cln3-deficient (Cln3−/−) neurons co-cultured with WT or
Cln3−/− mixed glia are shown in (A) and quantification of neuronal soma
size and neurite complexity under these different growth conditions are
shown in (B-D). Cln3−/− neurons co-cultured with Cln3−/− mixed glia had
a significantly smaller cell soma than did WT neurons co-cultured with
WT glia (Aa, Ad, quantified in B). The substitution of WT mixed glia for
Cln3−/− mixed glia significantly increased the soma size of Cln3−/− neurons (Ac,
Ad, quantified in B). The total length of primary neurites was significantly
reduced when Cln3−/− neurons were co-cultured with Cln3−/− mixed glia
compared to when WT neurons were co-cultured with WT glia (Aa, Ad,
quantified in C). The presence of Cln3−/− mixed glia also significantly
reduced the length of the longest primary neurite in both WT and Cln3
−/− neurons, and the length of the longest primary neurite was greater
when WT neurons were co-cultured with WT glia than when Cln3−/−
neurons were co-cultured with Cln3−/− mixed glia (C). The number of
primary neurites (1. neurites that are extended from cell bodies) did not
differ among the different co-cultures, but Cln3−/− mixed glia significantly
reduced the number of both secondary neurites (2. neurites that branch off
from primary neurites) and tertiary neurites (3. neurites that branch off from
secondary neurites) in Cln3−/− neurons (D). The presence of Cln3−/− mixed
glia also significantly reduced the number of tertiary neurites in WT neurons
(D). Scale bar in A = 20 μm. (TIFF 5626 kb)
Additional file 8: Figure S7. Altered astrocyte morphology in co-
cultures with Cln3−/− neurons. When co-cultured with Cln3-deficient
(Cln3−/−) neurons, Cln3−/− astrocytes (immunostained with GFAP, green)
changed shape, having smaller cell bodies and longer more numerous
processes (reminiscent of activated astrocytes in culture). No such
change was observed when Cln3−/− astrocytes were grown with wild
type (WT) neurons or when Cln3−/− neurons were grown with WT
astrocytes. Scale bar = 20 μm. Nuclear stain DAPI (blue), Live/dead stain
(red). (TIFF 10686 kb)
Acknowledgements
The generous assistance of Myriad RBM in running the protein secretion
assays is gratefully acknowledged. Natalie Masento (human section staining)
and Sashya De Silva (glutamine synthetase staining) are acknowledged for
their skilled assistance. Sybille Dihanich and Helen Brooks were recipients of
Medical Research Council DTA studentships, and Lotta Parviainen by an
Institute of Psychiatry, Psychology & Neuroscience departmental studentship.
Prof. Tammy Kielian, Dr. Jill Weimer, Dr. Alison Barnwell, Dr. Allison Najafi and
Dr. Hemanth Ramesh Nelvagal are thanked for their very useful comments
on the manuscript.
Funding
This study was supported by the Beyond Batten Disease Foundation, the
Batten Disease Support and Research Association (USA), the Batten Disease
Family Association (UK), the Saoirse Foundation and Irish Health Research
Board, The NCL Stiftung, The Children’s Brain Disease Foundation, The
Natalie Fund and the Bletsoe Family.
Authors’ contributions
The study was designed and supervised by JDC and BPW, with expert advice
and guidance from PR and HMM, and the input of all the authors. LP, SD
and GWA performed all aspects of the tissue culture experiments, and
analysed these data; AMS and HRB performed the pathology experiments;
the glutathione measurements were performed with and supervised by SP
and SJH; the calcium imaging experiments were performed with and
supervised by RA; the scratch assays were performed with and supervised by
GL; HMM also generated and provided the Cln3 deficient mice. The
manuscript was written by JDC, BPW, LP and SD with input from all the
authors, who approved the final version of the manuscript.
Ethics approval and consent to participate
All applicable international, national, and/or institutional guidelines for the
care and use of animals were followed. Specifically, all animal procedures
were performed in accordance with the UK Scientific Procedures (Animals)
Act of 1996, under the UK Home Office Project License number 70/7364. The
studies involving human autopsy material were in accordance with the
ethical standards of the Institute of Psychiatry Ethical Research Committee
(approval numbers 223/00, 181/02), and with the 1964 Helsinki declaration
and its later amendments or comparable ethical standards.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Basic and Clinical Neuroscience, King’s College London,
Institute of Psychiatry, Psychology & Neuroscience, Maurice Wohl Clinical
Neuroscience Institute, 5 Cutcombe Road, London SE5 9RX, UK. 2Department
of Molecular Neuroscience, Institute of Neurology, University College
London, Queen’s Square, London WC1N, 3BG, UK. 3Department of Life,
Health and Chemical Sciences, The Open University, Walton Hall, Milton
Keynes MK7 6AA, UK. 4Wolfson Centre for Age-Related Diseases, King’s
College London, London SE1 1UL, UK. 5Genetics and Genomic Medicine UCL
Great Ormond Street Institute of Child Health, University College London, 30
Guilford Street, London WC1N 1EH, UK. 6Department of Pediatrics,
Harbor-UCLA Medical Center, Los Angeles Biomedical Research Institute and
David Geffen School of Medicine UCLA, 1124 West Carson Street, Hanley
Hardison Building, Torrance, CA 90502, USA.
Parviainen et al. Acta Neuropathologica Communications  (2017) 5:74 Page 18 of 21
Received: 19 September 2017 Accepted: 23 September 2017
References
1. Allan SM, Rothwell NJ (2003) Inflammation in central nervous system injury.
Philos Trans R Soc Lond Ser B Biol Sci 358:1669–1677
2. Anderson GW, Goebel HH, Simonati A (2013) Human pathology in NCL.
Biochim Biophys Acta 1832:1807–1826
3. Anzai Y, Hayashi M, Fueki N, Kurata K, Ohya T (2006) Protracted juvenile
neuronal ceroid lipofuscinosis–an autopsy report and immunohistochemical
analysis. Brain and Development 28:462–465
4. Autti T, Raininko R, Santavuori P, Vanhanen SL, Poutanen VP, Haltia M (1997)
MRI of neuronal ceroid lipofuscinosis. II. Postmortem MRI and
histopathological study of the brain in 16 cases of neuronal ceroid
lipofuscinosis of juvenile or late infantile type. Neuroradiology 39:371–377
5. Benarroch EE (2013) Microglia: Multiple roles in surveillance, circuit shaping,
and response to injury. Neurology 81:1079–1088
6. Benedict JW, Sommers CA, Pearce DA (2007) Progressive oxidative damage
in the central nervous system of a murine model for juvenile Batten disease.
J Neurosci Res 85:2882–2891
7. Bethea JR, Nagashima H, Acosta MC, Briceno C, Gomez F, Marcillo AE, Loor
K, Green J, Dietrich WD (1999) Systemically administered interleukin-10
reduces tumor necrosis factor-alpha production and significantly improves
functional recovery following traumatic spinal cord injury in rats. J
Neurotrauma 16:851–863
8. Bible E, Gupta P, Hofmann SL, Cooper JD (2004) Regional and cellular
neuropathology in the palmitoyl protein thioesterase-1 null mutant
mouse model of infantile neuronal ceroid lipofuscinosis. Neurobiol Dis 16:
346–359
9. Bithell A, Finch SE, Hornby MF, Williams BP (2008) FGF2 maintains the
neurogenic capacity of embryonic neural progenitor cells in vitro but
changes their neuronal sub-type specification. Stem Cells 26:1565–1574
10. Björkblom B, Ostman N, Hongisto V, Komarovski V, Filén JJ, Nyman TA, Kallunki
T, Courtney MJ, Coffey ET (2005) Constitutively active cytoplasmic c-Jun N-
terminal kinase 1 is a dominant regulator of dendritic architecture: role of
microtubule-associated protein 2 as an effector. J Neurosci 25:6350–6361
11. Björkblom B, Padzik A, Mohammad H, Westerlund N, Komulainen E, Hollos
P, Parviainen L, Papageorgiou AC, Iljin K, Kallioniemi O, Kallajoki M, Courtney
MJ, Mågård M, James P, Coffey ET (2012) c-Jun N-terminal kinase
phosphorylation of MARCKSL1 determines actin stability and migration in
neurons and in cancer cells. Mol Cell Biol 32:3513–3526
12. Bolaños JP, Peuchen S, Heales SJ, Land JM, Clark JB (1994) Nitric oxide-
mediated inhibition of the mitochondrial respiratory chain in cultured
astrocytes. J Neurochem 63:910–916
13. Bond M, Holthaus SM, Tammen I, Tear G, Russell C (2013) Use of model
organisms for the study of neuronal ceroid lipofuscinosis. Biochim Biophys
Acta 1832:1842–1865
14. Brown GC, Bolaños JP, Heales SJ, Clark JB (1995) Nitric oxide produced by
activated astrocytes rapidly and reversibly inhibits cellular respiration.
Neurosci Lett 193:201–204
15. Bruno V, Copani A, Besong G, Scoto G, Nicoletti F (2000) Neuroprotective
activity of chemokines against N-methyl-D-aspartate or beta-amyloid-
induced toxicity in culture. Eur J Pharmacol 399:117–121
16. Burkovetskaya M, Karpuk N, Xiong J, Bosch M, Boska MD, Takeuchi H, Suzumura
A, Kielian T (2014) Evidence for aberrant astrocyte hemichannel activity in
Juvenile Neuronal Ceroid Lipofuscinosis (JNCL). PLoS One 9(4):e95023
17. Cayre M, Canoll P, Goldman JE (2009) Cell migration in the normal and
pathological postnatal mammalian brain. Prog Neurobiol 88:41–63
18. Chang M, Cooper JD, Sleat DE, Cheng SH, Dodge JC, Passini MA, Lobel P,
Davidson BL (2008) Intraventricular enzyme replacement improves disease
phenotypes in a mouse model of late infantile neuronal ceroid
lipofuscinosis. Mol Ther 16:649–656
19. Chao CC, Hu S, Ehrlich L, Peterson PK (1995) Interleukin-1 and tumor necrosis
factor-alpha synergistically mediate neurotoxicity: involvement of nitric oxide
and of N-methyl-D-aspartate receptors. Brain Behav Immun 9:355–365
20. Chattopadhyay S, Ito M, Cooper JD, Brooks AI, Curran TM, Powers JM, Pearce
DA (2002) An autoantibody inhibitory to glutamic acid decarboxylase in the
neurodegenerative disorderBatten disease. Hum Mol Genet 11:1421–1431
21. Chen G, Li H-M, Chen Y-R, Gu X-S, Duan S (2007) Decreased estradiol
release from astrocytes contributes to the neurodegeneration in a mouse
model of Niemann-Pick disease type C. Glia 55:1509–1518
22. Chow JC, Young DW, Golenbock DT, Christ WJ, Gusovsky F (1999) Toll-like
receptor-4 mediates lipopolysaccharide-induced signal transduction. J Biol
Chem 274:10689–10692
23. Cooper JD (2010) The neuronal ceroid lipofuscinoses: the same, but
different? Biochem Soc Trans 38:1448–1452
24. Cooper JD, Russell C, Mitchison HM (2006) Progress towards understanding
disease mechanisms in small vertebrate models of neuronal ceroid
lipofuscinosis. Biochim Biophys Acta 1762:873–889
25. Cooper JD, Tarczyluk MA, Nelvagal HR (2015) Towards a new understanding
of NCL pathogenesis. Biochim Biophys Acta 1852:2256–2261
26. Cortés-Vieyra R, Bravo-Patiño A, Valdez-Alarcón JJ, Cajero Juárez M, Finlay BB,
Baizabal-Aguirre VM (2012) Role of glycogen synthase kinase-3 beta in the
inflammatory response caused by bacterial pathogens. J Inflamm (Lond) 9:23
27. Cotrina ML, Lin JH-C, Nedergaard M (1998) Cytoskeletal Assembly and ATP
Release Regulate Astrocytic Calcium Signaling. J Neurosci 18:8794–8804
28. Di Malta C, Fryer JD, Settembre C, Ballabio A (2012a) Astrocyte dysfunction
triggers neurodegeneration in a lysosomal storage disorder. Proc Natl Acad
Sci U S A 109:E2334–E2342
29. Di Malta C, Fryer JD, Settembre C, Ballabio A (2012b) Autophagy in astrocytes:
A novel culprit in lysosomal storage disorders. Autophagy 8:1871–1872
30. Dietrich WD, Busto R, Bethea JR (1999) Postischemic hypothermia and IL-10
treatment provide long-lasting neuroprotection of CA1 hippocampus
following transient global ischemia in rats. Exp Neurol 158:444–450
31. Dringen R (2000) Metabolism and functions of glutathione in brain. Prog
Neurobiol 62:649–671
32. Finn R, Kovács AD, Pearce DA (2011) Altered sensitivity of cerebellar granule
cells to glutamate receptor overactivation in the Cln3(Δex7/8)-knock-in
mouse model of juvenile neuronal ceroid lipofuscinosis. Neurochem Int
58:648–655
33. Gegg ME, Clark JB, Heales SJR (2005) Co-culture of neurones with
glutathione deficient astrocytes leads to increased neuronal susceptibility
to nitric oxide and increased glutamate-cysteine ligase activity. Brain Res
1036:1–6
34. Getty AL, Benedict JW, Pearce DA (2011) A Novel interaction of CLN3 with
nonmuscle myosin-IIB and defects in cell motility of Cln3−/− cells. Exp Cell
Res 317:51–69
35. Giulian D, Ingeman JE (1988) Colony-stimulating factors as promoters of
ameboid microglia. J Neurosci 8:4707–4717
36. Hachiya Y, Hayashi M, Kumada S, Uchiyama A, Tsuchiya K, Kurata K (2006)
Mechanisms of neurodegeneration in neuronal ceroid-lipofuscinoses. Acta
Neuropathol 111:168–177
37. Haltia M, Herva R, Suopanki J, Baumann M, Tyynelä J (2001) Hippocampal
lesions in the neuronal ceroid lipofuscinoses. Eur J Paediatr Neurol. 5
(Suppl A):209–211
38. Hamby ME, Coppola G, Ao Y, Geschwind DH, Khakh BS, Sofroniew MV (2012)
Inflammatory mediators alter the astrocyte transcriptome and calcium signaling
elicited by multiple G-protein-coupled receptors. J Neurosci 32:14489–14510
39. Horvath CM (2004) The Jak-STAT pathway stimulated by interferon gamma.
Sci STKE 2004(260):tr8
40. Kielar C, Maddox L, Bible E, Pontikis CC, Macauley SL, Griffey MA, Wong M,
Sands MS, Cooper JD (2007) Successive neuron loss in the thalamus and
cortex in a mouse model of infantile neuronal ceroid lipofuscinosis.
Neurobiol Dis 25:150–162
41. Kovács AD, Pearce DA (2008) Attenuation of AMPA receptor activity
improves motor skills in a mouse model of juvenile Batten disease. Exp
Neurol 209:288–291
42. Kovács AD, Saje A, Wong A, Szénási G, Kiricsi P, Szabó E, Cooper JD, Pearce
DA (2011) Temporary inhibition of AMPA receptors induces a prolonged
improvement of motor performance in a mouse model of juvenile Batten
disease. Neuropharmacology 60:405–409
43. Kovács AD, Weimer JM, Pearce DA (2006) Selectively increased
sensitivity of cerebellar granule cells to AMPA receptor-mediated
excitotoxicity in a mouse model of Batten disease. Neurobiol Dis 22:
575–585
44. Kovács AD, Saje A, Wong A, Ramji S, Cooper JD, Pearce DA (2012) Age-
dependent therapeutic effect of memantine in a mouse model of juvenile
Batten disease. Neuropharmacology 63:769–775
45. Kreft M, Potokar M, Stenovec M, Pangrsic T, Zorec R (2009) Regulated
exocytosis and vesicle trafficking in astrocytes. Ann N Y Acad Sci 1152:30–42
46. Kuga N, Sasaki T, Takahara Y, Matsuki N, Ikegaya Y (2011) Large-scale calcium
waves traveling through astrocytic networks in vivo. J Neurosci 31:2607–2614
Parviainen et al. Acta Neuropathologica Communications  (2017) 5:74 Page 19 of 21
47. Kuronen M, Lehesjoki A-E, Jalanko A, Cooper JD, Kopra O (2012) Selective
spatiotemporal patterns of glial activation and neuron loss in the sensory
thalamocortical pathways of neuronal ceroid lipofuscinosis 8 mice.
Neurobiol Dis 47:444–457
48. Lau CL, O’Shea RD, Broberg BV, Bischof L, Beart PM (2011) The Rho kinase
inhibitor Fasudil up-regulates astrocytic glutamate transport subsequent
to actin remodelling in murine cultured astrocytes. Br J of Pharmacol 163:
533–545
49. Liddelow SA, Guttenplan KA, Clarke LE, Bennett FC, Bohlen CJ, Schirmer L,
Bennett ML, Münch AE, Chung W-S, Peterson TC, Wilton DK, Frouin A,
Napier BA, Panicker N, Kumar M, Buckwalter MS, Rowitch DH, Dawson VL,
Dawson TM, Stevens B, Barres BA (2017) Neurotoxic reactive astrocytes are
induced by activated microglia. Nature 541:481–487
50. Lim MJ, Alexander N, Benedict JW, Chattopadhyay S, Shemilt SJ, Guérin CJ,
Cooper JD, Pearce DA (2007) IgG entry and deposition are components of
the neuroimmune response in Batten disease. Neurobiol Dis 25:239–251
51. Lucas S-M, Rothwell NJ, Gibson RM (2006) The role of inflammation in CNS
injury and disease. Br J Pharmacol 147(Suppl 1):S232–S240
52. McCarthy KD, de Vellis J (1980) Preparation of separate astroglial and
oligodendroglial cell cultures from rat cerebral tissue. J Cell Biol 85:890–902
53. McMillian M, Thai L, Hong JS, O’Callaghan JP, Pennypacker KR (1994) Brain
injury in a dish: a model for reactive gliosis. Trends in Neuroscience 17:138–142
54. Macauley SL, Roberts MS, Wong AMS, McSloy F, Reddy AS, Cooper JD,
Sands MS (2012) Synergistic effects of CNS-directed gene therapy and bone
marrow transplantation in the murine model of infantile neuronal ceroid
lipofuscinosis. Ann Neurol 71:797–804
55. Mangano EN, Peters S, Litteljohn D, So R, Bethune C, Bobyn J, Clarke M,
Hayley S (2011) Granulocyte macrophage-colony stimulating factor protects
against substantia nigra dopaminergic cell loss in an environmental toxin
model of Parkinson's disease. Neurobiol Dis 43:99–112
56. Mitchison HM, Bernard DJ, Greene ND, Cooper JD, Junaid MA, Pullarkat RK,
de Vos N, Breuning MH, Owens JW, Mobley WC, Gardiner RM, Lake BD,
Taschner PE, Nussbaum RL (1999) Targeted disruption of the Cln3 gene
provides a mouse model for Batten disease. The Batten Mouse Model
Consortium [corrected]. Neurobiol Dis 6:321–334
57. Moidunny S, Dias RB, Wesseling E, Sekino Y, Boddeke HWGM, Sebastião AM,
Biber K (2010) Interleukin-6-type cytokines in neuroprotection and
neuromodulation: oncostatin M, but not leukemia inhibitory factor, requires
neuronal adenosine A1 receptor function. J Neurochem 114:1667–1677
58. Mole SE, Williams R, Goebel H (2011) The Neuronal Ceroid Lipofuscinoses
(Batten Disease). Oxford Univ Press, Oxford
59. Morgan JP, Magee H, Wong A, Nelson T, Koch B, Cooper JD, Weimer JM
(2013) A murine model of variant late infantile ceroid lipofuscinosis
recapitulates behavioral and pathological phenotypes of human disease.
PLoS One 8:e78694
60. Nobile M, Monaldi I, Alloisio S, Cugnoli C, Ferroni S (2003) ATP-induced,
sustained calcium signalling in cultured rat cortical astrocytes: evidence for
a non-capacitative, P2X7-like-mediated calcium entry. FEBS Lett 538:71–76
61. Oswald MJ, Palmer DN, Kay GW, Shemilt SJA, Rezaie P, Cooper JD (2005)
Glial activation spreads from specific cerebral foci and precedes
neurodegeneration in presymptomatic ovine neuronal ceroid lipofuscinosis
(CLN6). Neurobiol Dis 20:49–63
62. Oudin MJ, Gajendra S, Williams G, Hobbs C, Lalli G, Doherty P (2011)
Endocannabinoids regulate the migration of subventricular zone-derived
neuroblasts in the postnatal brain. J Neurosci 31:4000–4011
63. Palmer DN, Barry LA, Tyynelä J, Cooper JD (2013) NCL disease mechanisms.
Biochim Biophys Acta 1832:1882–1893
64. Partanen S, Haapanen A, Kielar C, Pontikis C, Alexander N, Inkinen T, Saftig P,
Gillingwater TH, Cooper JD, Tyynelä J (2008) Synaptic changes in the
thalamocortical system of cathepsin D deficient mice, a model of human
congenital neuronal ceroid- lipofuscinosis. J Neuropathol Exp Neurol 67:16–29
65. Pears MR, Cooper JD, Mitchison HM, Mortishire-Smith RJ, Pearce DA, Griffin
JL (2005) High resolution 1H NMR-based metabolomics indicates a
neurotransmitter cycling deficit in cerebral tissue from a mouse model of
Batten disease. J Biol Chem 280:42508–42514
66. Pekny M, Pekna M, Messing A, Steinhäuser C, Lee JM, Parpura V, Hol EM,
Sofroniew MV, Verkhratsky A (2016) Astrocytes: a central element in
neurological diseases. Acta Neuropathol 131(3):323–345
67. Pinto DJ, Patrick SL, Huang WC, Connors BW (2005) Initiation, propagation,
and termination of epileptiform activity in rodent neocortex in vitro involve
distinct mechanisms. J Neurosci 25:8131–8140
68. Pontikis CC, Cella CV, Parihar N, Lim MJ, Chakrabarti S, Mitchison HM, Mobley
WC, Rezaie P, Pearce DA, Cooper JD (2004) Late onset neurodegeneration in
the Cln3−/− mouse model of juvenile neuronal ceroid lipofuscinosis is
preceded by low level glial activation. Brain Res 1023:231–242
69. Pontikis CC, Cotman SL, MacDonald ME, Cooper JD (2005) Thalamocortical
neuron loss and localized astrocytosis in the Cln3Deltaex7/8 knock-in
mouse model of Batten disease. Neurobiol Dis 20:823–836
70. Potokar M, Kreft M, Li L, Daniel Andersson J, Pangrsic T, Chowdhury HH,
Pekny M, Zorec R (2007) Cytoskeleton and vesicle mobility in astrocytes.
Traffic 8:12–20
71. Pressey SN, Smith DA, Wong AMS, Platt FM, Cooper JD (2012) Early glial
activation, synaptic changes and axonal pathology in the thalamocortical
system of Niemann-Pick type C1 mice. Neurobiol Dis 45:1086–1100
72. Ransohoff RM (2009) Chemokines and chemokine receptors: standing at the
crossroads of immunobiology and neurobiology. Immunity 31:711–721
73. Ransohoff RM, Brown MA (2012) Innate immunity in the central nervous
system. J Clin Invest 122:1164–1171
74. Rossi F, Bianchini E (1996) Synergistic induction of nitric oxide by beta-
amyloid and cytokines in astrocytes. Biochem Biophys Res Commun 225:
474–478
75. Rossi D, Volterra A (2009) Astrocytic dysfunction: insights on the role in
neurodegeneration. Brain Res Bull 80:224–232
76. Schäbitz WR, Krüger C, Pitzer C, Weber D, Laage R, Gassler N, Aronowski J,
Mier W, Kirsch F, Dittgen T, Bach A, Sommer C, Schneider A (2008) A
neuroprotective function for the hematopoietic protein granulocyte-
macrophage colony stimulating factor (GM-CSF). J Cereb Blood Flow Metab
28:29–43
77. Schmiedt M-L, Blom T, Blom T, Kopra O, Wong A, Schantz-Fant von C,
Ikonen E, Kuronen M, Jauhiainen M, Cooper JD, Jalanko A (2012) Cln5-
deficiency in mice leads to microglial activation, defective myelination and
changes in lipid metabolism. Neurobiol Dis 46:19–29
78. Schulz JB, Lindenau J, Seyfried J, Dichgans J (2000) Glutathione, oxidative
stress and neurodegeneration. Eur J Biochem 267:4904–4911
79. Schulz A, Kohlschütter A, Mink J, Simonati A, Williams R (2013) NCL diseases
- clinical perspectives. Biochim Biophys Acta 1832:1801–1806
80. Seehafer SS, Ramirez-Montealegre D, Wong AM, Chan C-H, Castaneda J,
Horak M, Ahmadi SM, Lim MJ, Cooper JD, Pearce DA (2011)
Immunosuppression alters disease severity in juvenile Batten disease mice.
J Neuroimmunol 230:169–172
81. Semple BD, Kossmann T, Morganti-Kossmann MC (2010) Role of chemokines in
CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2
networks. J Cereb Blood Flow Metab 30:459–473
82. Shacka JJ (2012) Mouse models of neuronal ceroid lipofuscinoses: useful
pre-clinical tools to delineate disease pathophysiology and validate
therapeutics. Brain Res Bull 88:43–57
83. Singh S, Swarnkar S, Goswami P, Nath C (2011) Astrocytes and microglia:
responses to neuropathological conditions. Int J Neurosci 121:589–597
84. Sleat DE, Wiseman JA, El-Banna M, Kim K-H, Mao Q, Price S, Macauley SL, Sidman
RL, Shen MM, Zhao Q, Passini MA, Davidson BL, Stewart GR, Lobel P (2004) A
mouse model of classical late-infantile neuronal ceroid lipofuscinosis based on
targeted disruption of the CLN2 gene results in a loss of tripeptidyl-peptidase I
activity and progressive neurodegeneration. J Neurosci 24:9117–9126
85. Sofroniew MV, Vinters HV (2010) Astrocytes: biology and pathology. Acta
Neuropathol 119:7–35
86. Stewart VC, Stone R, Gegg ME, Sharpe MA, Hurst RD, Clark JB, Heales SJ
(2002) Preservation of extracellular glutathione by an astrocyte derived
factor with properties comparable to extracellular superoxide dismutase.
J Neurochem 83:984–991
87. Suzumura A, Sawada M, Yamamoto H, Marunouchi T (1990) Effects of
colony stimulating factors on isolated microglia in vitro. J Neuroimmunol
30:111–120
88. Trevelyan AJ, Sussillo D, Watson BO, Yuste R (2006) Modular propagation of
epileptiform activity: evidence for an inhibitory veto in neocortex. J Neurosci
26:12447–12455
89. Tuxworth RI, Chen H, Vivancos V, Carvajal N, Huang X, Tear G (2011) The
Batten disease gene CLN3 is required for the response to oxidative stress.
Hum Mol Genet 20:2037–2047
90. Tyynelä J, Cooper JD, Khan MN, Shemilt SJA, Haltia M (2004) Hippocampal
pathology in the human neuronal ceroid—lipofuscinoses: distinct patterns
of storage deposition, neurodegeneration and glial activation. Brain Pathol
14:349–357
Parviainen et al. Acta Neuropathologica Communications  (2017) 5:74 Page 20 of 21
91. Verity C, Winstone AM, Stellitano L, Will R, Nicoll A (2010) The epidemiology
of progressive intellectual and neurological deterioration in childhood. Arch
Dis Child 95:361–364
92. Verkhratsky A (2010) Physiology of neuronal-glial networking. Neurochem
Int 57:332–343
93. von Schantz C, Kielar C, Hansen SN, Pontikis CC, Alexander NA, Kopra O,
Jalanko A, Cooper JD (2009) Progressive thalamocortical neuron loss in Cln5
deficient mice: distinct effects in Finnish variant late infantile NCL. Neurobiol
Dis 34:308–319
94. Wang D, Baldwin AS (1998) Activation of nuclear factor-kappaB-dependent
transcription by tumor necrosis factor-alpha is mediated through
phosphorylation of RelA/p65 on serine 529. J Biol Chem 273:29411–29416
95. Wang XQ, Peng YP, Lu JH, Cao BB, Qiu YH (2009) Neuroprotection of
interleukin-6 against NMDA attack and its signal transduction by JAK and
MAPK. Neurosci Lett, 450:122–126
96. Warrier V, Vieira M, Mole SE (2013) Genetic basis and phenotypic correlations
of the neuronal ceroid lipofusinoses. Biochim Biophys Acta 1832:1827–1830
97. Williams BP, Price J (1995) Evidence for multiple precursor cell types in the
developing rat cerebral cortex. Neuron 14:1181–1188
98. Witting A, Möller T (2011) Microglia cell culture: a primer for the novice.
Methods Mol Biol 758:49–66
99. Xiong J, Kielian T (2013) Microglia in juvenile neuronal ceroid lipofuscinosis are
primed toward a pro-inflammatory phenotype. J Neurochem 127:245–258
100. Zambrano A, Otth C, Mujica L, Concha II, Maccioni RB (2007) Interleukin-3
prevents neuronal death induced by amyloid peptide. BMC Neurosci 8:82
101. Zambrano A, Otth C, Maccioni RB, Concha II (2010) IL-3 controls tau
modifications and protects cortical neurons from neurodegeneration. Curr
Alzheimer Res 7:615–624
102. Zhang M, Strnatka D, Donohue C, Hallows JL, Vincent I, Erickson RP (2008)
Astrocyte-only Npc1 reduces neuronal cholesterol and triples life span of
Npc1−/− mice. J Neurosci Res 86:2848–2856
103. Zorec R, Araque A, Carmignoto G, Haydon PG, Verkhratsky A, Parpura V
(2012) Astroglial excitability and gliotransmission: an appraisal of Ca2+ as a
signalling route. ASN Neuro 4:103–119
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Parviainen et al. Acta Neuropathologica Communications  (2017) 5:74 Page 21 of 21
